C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF...
Q2 2026
Aug 6, 2026
Q1 2026
May 12, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 6, 2025
